Day One Biopharmaceuticals Receivables

Day One Biopharmaceuticals (DAWN) currently reports a receivables of $27M as of December 2025. That compares with $14M in the prior-year period — up 92.7% year over year. Use the charts on this page to explore Day One Biopharmaceuticals's receivables history and peer comparisons.

Day One Biopharmaceuticals's receivables increased from $14M to $27M — a 92.7% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Day One Biopharmaceuticals reported $27M in receivables as of December 2025. That compares with $14M in the prior-year period — up 92.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Day One Biopharmaceuticals, and consider following DAWN for alerts when major investors trade the stock.

Day One Biopharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $27M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DAWN with unrelated industries.